MONTVILLE, NJ-The FDA has approved Campath (alemtuzumab) humanized monoclonal antibody for the treatment of patients with B-cell chronic lymphocytic leukemia (CLL) who have been treated with alkylating agents and have failed fludarabine (Fludara) therapy. Campath was developed by M&I Partners, a 50-50 joint venture of Millennium Pharmaceuticals, Inc. and ILEX Oncology, Inc. The agent will be marketed and distributed in the United States by Berlex Laboratories, Inc.
MONTVILLE, NJThe FDA has approved Campath (alemtuzumab) humanized monoclonal antibody for the treatment of patients with B-cell chronic lymphocytic leukemia (CLL) who have been treated with alkylating agents and have failed fludarabine (Fludara) therapy. Campath was developed by M&I Partners, a 50-50 joint venture of Millennium Pharmaceuticals, Inc. and ILEX Oncology, Inc. The agent will be marketed and distributed in the United States by Berlex Laboratories, Inc.
Campath binds to CD52, an antigen present on the surface of certain leukemia lymphocytes, which induces antibody-dependent cell lysis.
Approval was based on results of one large single-arm trial and two smaller studies showing overall response rates of 33%, 21%, and 29%, and median duration of response of 7 months, 7 months, and 11 months, respectively.
Due to excess mortality attributed to therapy-related complications in these studies, Campath will include a boxed warning concerning therapy-related hematologic toxicity, infusion reactions, and infections. For prescribing information, see www.berlex.com.
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Jeffrey Chamberlain, PhD, on the Import of Early Intervention in DMD
July 10th 2025The McCaw Endowed Chair of Muscular Dystrophy at University of Washington, discussed how comprehensive care for DMD patients involves early diagnosis, steroid treatment, consideration of mutation-specific therapies, and more.